Ritu Salani, MD

Ritu Salani, MD, MBA, is a board-certified gynecologic oncologist who is a nationally renowned expert in the treatment of gynecologic malignancies with over 15 years of experience. She serves as the Director of Gynecologic Oncology at UCLA.

Articles

Recently Presented Data on Endometrial Cancer

July 27th 2023

The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.

MIRASOL Trial: Mirvetuximab in Platinum-Resistant Ovarian Cancer

July 20th 2023

Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.

Ongoing Trials on Maintenance Therapy in Recurrent Ovarian Cancer

July 20th 2023

A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.

Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer

July 13th 2023

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Efficacy of Subsequent Therapies in Advanced Ovarian Cancer

July 13th 2023

Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.

Recent Data on PARP Inhibitors as First-Line Maintenance in Ovarian Cancer

July 6th 2023

A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.

Unmet Needs in the Maintenance Setting in Ovarian Cancer

July 6th 2023

An expert panel highlights current unmet needs in the maintenance setting for ovarian cancer.

Ovarian Cancer: Deciding Between Treatment Options

June 29th 2023

Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.

Frontline Maintenance Therapy in Ovarian Cancer

June 29th 2023

A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.

Dr. Salani on the Role of HER2 Expression in Advanced Uterine Serous Carcinoma

November 22nd 2022

Ritu Salani, MD, MBA, discusses the role of HER2 expression on treatment decisions in advanced uterine serous carcinomas.

Dr. Salani on Updates in Treating Endometrial Cancer

November 15th 2022

Ritu Salani, MD, MBA, discusses updates in treating endometrial cancer.

Dr. Salani on the Role of Molecular Profiling in Endometrial Cancer Treatment

November 1st 2022

Ritu Salani, MD, MBA, discusses the importance of histological subtyping and molecular profiling in developing treatment strategies and improving outcomes for patients with endometrial cancer.

Dr. Salani on Future Research Opportunities in Recurrent Ovarian Cancer

October 29th 2021

Ritu Salani, MD, MBA, discusses future research opportunities for improving the treatment of patients with recurrent ovarian cancer.

Dr. Salani on the Rationale for Immunotherapy/PARP Inhibitor Combos in Ovarian Cancer

October 4th 2021

Ritu Salani, MD, MBA, discusses the rationale for combinations of immunotherapy and PARP inhibitors in ovarian cancer.

Dr. Salani on the Potential Impact of Ongoing Research in Ovarian Cancer

September 22nd 2021

Ritu Salani, MD, MBA, discusses the scope of ongoing research in advanced ovarian cancer.

Dr. Salani on Therapeutic Advances in Endometrial Cancer

November 2nd 2020

Ritu Salani, MD, MBA, discusses therapeutic advances in endometrial cancer.

Dr. Salani on the Current State of Biomarker Testing in Cervical Cancer

July 8th 2020

Ritu Salani, MD, MBA, discusses the current state of biomarker testing in cervical cancer.

Dr. Salani on Opportunities for Precision Medicine in Cervical Cancer

June 11th 2020

Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.

Dr. Salani on Opportunities for Precision Medicine in Cervical Cancer

June 10th 2020

Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.

Dr. Salani on Choosing Among IV, IP, and Dose-Dense Chemo Regimens in Ovarian Cancer

March 26th 2020

Ritu Salani, MD, provides insight into how to approach selection of chemotherapy in ovarian cancer.